Recap: Veru Q1 Earnings

Shares of Veru VERU moved higher by 17.6% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 60.00% year over year to ($0.02), which beat the estimate of ($0.06).

Revenue of $14,617,000 higher by 38.18% from the same period last year, which beat the estimate of $10,570,000.

Looking Ahead

Veru hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Feb 10, 2021

Time: 08:00 AM

ET Webcast URL: https://verupharma.com/investors/presentations-conference-calls/

Technicals

52-week high: $24.57

Company's 52-week low was at $2.30

Price action over last quarter: Up 279.56%

Company Profile

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States.